Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 4
1987 1
1992 1
1993 3
1994 2
1995 3
1996 1
1998 4
1999 1
2000 1
2001 4
2002 16
2003 23
2004 49
2005 66
2006 91
2007 94
2008 82
2009 106
2010 88
2011 91
2012 97
2013 99
2014 116
2015 94
2016 90
2017 78
2018 63
2019 67
2020 72
2021 68
2022 62
2023 73
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

1,488 results

Results by year

Filters applied: . Clear all
Page 1
Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.
Caballero J, Nahata MC. Caballero J, et al. Clin Ther. 2003 Dec;25(12):3065-83. doi: 10.1016/s0149-2918(03)90092-0. Clin Ther. 2003. PMID: 14749146 Review.
Although these drugs are the mainstay of treatment for ADHD, nearly one third of patients may not respond to or be able to tolerate them. Atomoxetine hydrochloride, a nonstimulant approved by the US Food and Drug Administration for the treatment of ADHD, may provide …
Although these drugs are the mainstay of treatment for ADHD, nearly one third of patients may not respond to or be able to tolerate them. …
Current Pharmacological Treatments for ADHD.
Groom MJ, Cortese S. Groom MJ, et al. Curr Top Behav Neurosci. 2022;57:19-50. doi: 10.1007/7854_2022_330. Curr Top Behav Neurosci. 2022. PMID: 35507282 Review.
Currently approved pharmacological treatments for ADHD include a range of stimulant (methylphenidate, amphetamine) and nonstimulant (atomoxetine, guanfacine, clonidine) medications. All have been shown to be effective in treating the symptoms of ADHD and improving other fu …
Currently approved pharmacological treatments for ADHD include a range of stimulant (methylphenidate, amphetamine) and nonstimulant (atom …
Evidence-based pharmacological treatment options for ADHD in children and adolescents.
Mechler K, Banaschewski T, Hohmann S, Häge A. Mechler K, et al. Pharmacol Ther. 2022 Feb;230:107940. doi: 10.1016/j.pharmthera.2021.107940. Epub 2021 Jun 23. Pharmacol Ther. 2022. PMID: 34174276 Free article. Review.
Available medications include stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine, guanfacine, clonidine). While available pharmacological treatment options for ADHD show relatively large effect sizes (in short-term trials) and overall good tolerabil …
Available medications include stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine, guanfacine, clonidine). Whi …
Nonstimulant Treatments for ADHD.
Newcorn JH, Krone B, Dittmann RW. Newcorn JH, et al. Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):417-435. doi: 10.1016/j.chc.2022.03.005. Epub 2022 May 11. Child Adolesc Psychiatr Clin N Am. 2022. PMID: 35697393 Review.
We present detailed information regarding the 4 FDA-approved nonstimulant medications-the norepinephrine reuptake inhibitors, atomoxetine and viloxazine extended release, and the alpha-2 adrenergic agonists, clonidine XR and guanfacine XR. ...
We present detailed information regarding the 4 FDA-approved nonstimulant medications-the norepinephrine reuptake inhibitors, atomoxetine …
Atomoxetine hydrochloride.
Garland M, Kirkpatrick P. Garland M, et al. Nat Rev Drug Discov. 2004 May;3(5):385-6. doi: 10.1038/nrd1387. Nat Rev Drug Discov. 2004. PMID: 15152632 No abstract available.
The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial.
Schweitzer PK, Taranto-Montemurro L, Ojile JM, Thein SG, Drake CL, Rosenberg R, Corser B, Abaluck B, Sangal RB, Maynard J. Schweitzer PK, et al. Am J Respir Crit Care Med. 2023 Dec 15;208(12):1316-1327. doi: 10.1164/rccm.202306-1036OC. Am J Respir Crit Care Med. 2023. PMID: 37812772 Free PMC article. Clinical Trial.
Objectives: The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic agent aroxybutynin and the norepinephrine reuptake inhibitor atomoxetine, in the treatment of OSA. Methods: Phase II randomized, double-blind, plac …
Objectives: The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic agent aroxybut …
Atomoxetine in-focus!
Naguy A, Al-Enezi N, AlShalabi SR. Naguy A, et al. Asian J Psychiatr. 2020 Mar;49:101634. doi: 10.1016/j.ajp.2019.02.008. Epub 2019 Feb 13. Asian J Psychiatr. 2020. PMID: 30797701 No abstract available.
Effects of Atomoxetine Hydrochloride on Regulation of Lifespan in Drosophila Model.
Shen J, Shan J, Liang B, Zhang D, Tang H, Zhong L, Li M. Shen J, et al. J Nutr Health Aging. 2022;26(2):203-208. doi: 10.1007/s12603-022-1741-8. J Nutr Health Aging. 2022. PMID: 35166316 Free article.
Are there nootropics that can improve learning behavior while having potential positive effect on health? Here, we reported that Atomoxetine (ATX) has sex-specific effect on prolonging the life span of female Drosophila melanogaster. ...
Are there nootropics that can improve learning behavior while having potential positive effect on health? Here, we reported that Atomoxet …
The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
Pringsheim T, Hirsch L, Gardner D, Gorman DA. Pringsheim T, et al. Can J Psychiatry. 2015 Feb;60(2):42-51. doi: 10.1177/070674371506000202. Can J Psychiatry. 2015. PMID: 25886655 Free PMC article. Review.
METHOD: We performed a systematic review and meta-analysis of psychostimulants, alpha-2 agonists, and atomoxetine for oppositional behaviour, conduct problems, and aggression in youth with ADHD, ODD, and CD. ...CONCLUSIONS: Evidence indicates that psychostimulants, alpha-2 …
METHOD: We performed a systematic review and meta-analysis of psychostimulants, alpha-2 agonists, and atomoxetine for oppositional be …
The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.
Taranto-Montemurro L, Messineo L, Sands SA, Azarbarzin A, Marques M, Edwards BA, Eckert DJ, White DP, Wellman A. Taranto-Montemurro L, et al. Am J Respir Crit Care Med. 2019 May 15;199(10):1267-1276. doi: 10.1164/rccm.201808-1493OC. Am J Respir Crit Care Med. 2019. PMID: 30395486 Free PMC article. Clinical Trial.
Methods: A total of 20 people completed a randomized, placebo-controlled, double-blind, crossover trial comparing 1 night of 80 mg atomoxetine plus 5 mg oxybutynin (ato-oxy) to placebo administered before sleep. ...Genioglossus responsiveness increased approximately threef …
Methods: A total of 20 people completed a randomized, placebo-controlled, double-blind, crossover trial comparing 1 night of 80 mg atomox …
1,488 results